"After the transaction, Denselight sales are gone as well as expenses. 100%? Less? How many people will stay on POET´s payroll? Is the complete product line sold together with DL?"
Hard to know what expenses will remain. Looking at financials we see 2018 R & D costs of ~$8.7M, of which only $3.5M were in Singapore with the remainder in North America. Surprising to me the R&D costs in the US were higher than in Singapore (where I thought the bulk of the R&D was being carried out!). Seems significant work being done in the US. and begs the questions: by who and how many; what is being done; and, where is this being done (certainly not in Suresh's San Jose office)?
|
Year Ended December 31, 2018
|
Singapore
|
US
|
Canada
|
Consolidated
|
|
Revenue
|
$ 3,888,185
|
$ -
|
$ -
|
$ 3,888,185
|
|
Cost of revenue
|
$ 1,745,969
|
$ -
|
$ -
|
$ 1,745,969
|
|
Selling, marketing and administration
|
$ 8,252,278
|
$ 2,337,342
|
$ 1,099,584
|
$ 11,689,204
|
|
Research and Development
|
$ 3,533,994
|
$ 4,706,817
|
$ 451,993
|
$ 8,692,804
|
|
Impairment loss
|
$ 156,717
|
$ -
|
$ -
|
$ 156,717
|
|
Other income including interest income
|
-$ 1,491,556
|
$ -
|
-$ 14,234
|
-$ 1,505,790
|
| |
|
|
|
|
|
Net loss from operations before income tax recovery
|
$ 8,039,217
|
$ 7,044,159
|
$ 1,537,343
|
$ 16,620,719
|
